Taysha Gene Therapies, Inc. (TSHA) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 0 | 5.49M | 0 | 1.99M | 2.3M | 2.02M | 1.79M | 1.11M | 3.41M | 3.6M | 4.75M | 2.4M |
| Revenue Growth % | -100% | 171.27% | -100% | 78.6% | -32.51% | -43.9% | -62.33% | -53.57% | -27.52% | 44.04% | - | - |
| Cost of Goods Sold | 0 | 299K | 286K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 331K | 703K |
| COGS % of Revenue | - | 5.45% | - | - | - | - | - | - | - | - | 6.97% | 29.35% |
| Gross Profit | 0 | 5.19M | -286K | 1.99M | 2.3M | 2.02M | 1.79M | 1.11M | 3.41M | 3.6M | 4.42M | 1.69M |
| Gross Margin % | - | 94.55% | - | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 93.03% | 70.65% |
| Gross Profit Growth % | -100% | 156.48% | -116% | 78.6% | -32.51% | -43.9% | -59.5% | -34.28% | -16.29% | 337.91% | - | - |
| Operating Expenses | 43.49M | 33.49M | 33.74M | 28.74M | 23.72M | 21.95M | 27.69M | 22.41M | 27.74M | 19.85M | 20.05M | 25.08M |
| OpEx % of Revenue | - | 610.5% | - | 1447.08% | 1030.54% | 1085.76% | 1548.43% | 2015.38% | 813.28% | 550.78% | 422.44% | 1047.01% |
| Selling, General & Admin | 9.68M | 8.83M | 8.28M | 8.6M | 8.16M | 6.63M | 7.9M | 7.34M | 7.08M | 6.72M | 8.26M | 5.29M |
| SG&A % of Revenue | - | 161.04% | - | 432.93% | 354.39% | 327.84% | 441.95% | 659.89% | 207.68% | 186.43% | 174% | 220.67% |
| Research & Development | 33.81M | 24.65M | 25.46M | 20.14M | 15.56M | 15.32M | 14.95M | 15.07M | 20.66M | 12.68M | 11.79M | 19.79M |
| R&D % of Revenue | - | 449.46% | - | 1014.15% | 676.15% | 757.91% | 835.91% | 1355.49% | 605.6% | 351.89% | 248.44% | 826.35% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 1000K | 0 | 0 | 449K | 0 | 0 |
| Operating Income | -43.49M | -28.3M | -34.02M | -26.75M | -21.42M | -19.93M | -25.9M | -21.3M | -24.33M | -16.25M | -15.63M | -23.38M |
| Operating Margin % | - | -515.95% | - | -1347.08% | -930.54% | -985.76% | -1448.43% | -1915.38% | -713.28% | -450.78% | -329.41% | -976.37% |
| Operating Income Growth % | -103.01% | -41.98% | -31.38% | -25.61% | 11.96% | -22.69% | -65.65% | 8.92% | -46.93% | 13.12% | 38.59% | 29.93% |
| EBITDA | -43.49M | -28M | -33.74M | -26.48M | -21.14M | -19.63M | -25.6M | -20.98M | -24M | -15.88M | -15.3M | -22.68M |
| EBITDA Margin % | - | -510.5% | - | -1333.13% | -918.24% | -970.72% | -1431.99% | -1886.42% | -703.75% | -440.62% | -322.44% | -947.01% |
| EBITDA Growth % | -105.72% | -42.66% | -31.77% | -26.21% | 11.94% | -23.6% | -67.31% | 7.51% | -50.71% | 6.7% | 39.23% | 31.48% |
| D&A (Non-Cash Add-back) | 0 | 299K | 286K | 277K | 283K | 304K | 294K | 322K | 325K | 366K | 331K | 703K |
| EBIT | 0 | -28.3M | -32.72M | -26.86M | -21.51M | -18.76M | -25.5M | -20.9M | -24.03M | 48.45M | -115.62M | -23.16M |
| Net Interest Income | 0 | 2.86M | 3.15M | 1.84M | 1.31M | 1.68M | 2.08M | 1.41M | 1.66M | 1.21M | -362K | -1.22M |
| Interest Income | 2.59M | 2.87M | 3.17M | 1.86M | 1.33M | 1.7M | 2.11M | 1.44M | 1.69M | 1.92M | 1.11M | 223K |
| Interest Expense | -9K | 12K | 15K | 17K | 19K | 22K | 24K | 27K | 29K | 713K | 1.47M | 1.44M |
| Other Income/Expense | 1.08M | 449K | 1.29M | -129K | -108K | 1.15M | 374K | 371K | 269K | 63.99M | -101.45M | -1.21M |
| Pretax Income | -42.41M | -27.85M | -32.73M | -26.88M | -21.53M | -18.79M | -25.52M | -20.93M | -24.06M | 47.74M | -117.09M | -24.6M |
| Pretax Margin % | - | -507.77% | - | -1353.58% | -935.23% | -929.03% | -1427.52% | -1882.01% | -705.39% | 1324.67% | -2467.07% | -1027.06% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -42.41M | -27.85M | -32.73M | -26.88M | -21.53M | -18.79M | -25.52M | -20.93M | -24.06M | 47.74M | -117.09M | -24.6M |
| Net Margin % | - | -507.77% | - | -1353.58% | -935.23% | -929.03% | -1427.52% | -1882.01% | -705.39% | 1324.67% | -2467.07% | -1027.06% |
| Net Income Growth % | -96.99% | -48.26% | -28.24% | -28.45% | 10.52% | -139.35% | 78.2% | 14.92% | -36.54% | 185.68% | -341.39% | 27.85% |
| Net Income (Continuing) | -42.41M | -27.85M | -32.73M | -26.88M | -21.53M | -18.79M | -25.52M | -20.93M | -24.06M | 47.74M | -117.09M | -24.6M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.12 | -0.08 | -0.09 | -0.09 | -0.08 | -0.09 | -0.10 | -0.09 | -0.10 | 0.26 | -0.93 | -0.38 |
| EPS Growth % | -50.19% | 12.76% | 2.83% | -0.33% | 20.1% | -135.9% | 89.77% | 76.52% | 64.11% | 125.85% | -43.75% | 54.92% |
| EPS (Basic) | -0.12 | -0.08 | -0.09 | -0.09 | -0.08 | -0.09 | -0.10 | -0.09 | -0.10 | 0.26 | -0.93 | -0.38 |
| Diluted Shares Outstanding | 366.63M | 319.71M | 353.31M | 297.99M | 269.31M | 204.94M | 267.82M | 232.82M | 231.25M | 186.96M | 125.7M | 64.24M |
| Basic Shares Outstanding | 366.63M | 319.71M | 353.31M | 297.99M | 269.31M | 204.94M | 267.82M | 232.82M | 231.25M | 186.96M | 125.7M | 64.24M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |